Spago Nanomedical AB has announced it has signed an agreement with the Cmed Group for the development of the first clinical study to assess safety and demonstrate proof-of-concept in aggressive cancer patients with the company’s therapy project Tumorad®.
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors.
Press release by Spago Nanomedical AB